Phase II study of intravenous Doxil® in malignant pleural mesothelioma

Investigational New Drugs

Volumn 18, Issue 3, 2000, Pages 243-245

  Oh, Yun ^a   Perez Soler, Roman ^a   Fossella, Frank V ^a   Glisson, Bonnie S ^a   Kurie, Jonathan ^a   Walsh, Garrett L ^a   Truong, Mylene ^a   Shin, Dong M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Doxil ; Mesothelioma

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRONCHOSPASM; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DYSESTHESIA; ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; MALE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; SKIN TOXICITY; SURVIVAL TIME;

AGED; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS;

EID: 0033899476     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006421706540     Document Type: Article

References (7)

1. Sterman DH, Kaiser LR, Albelda SM: Advances in the treatment of malignant pleural mesotheliomal. Chest 116: 504-520, 1999
2. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, DeCamp MM Jr, Swanson SJ, Bueno R, Lukanich JM, Baldini EH, Mentzer SJ: Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117:54-63, 1999
3. Ryan CW, Herndon J, Vogelzang NJ: A review of chemotherapy trials for malignant mesothelioma. Chest 113(suppl): 66S-73S, 1998
4. Shin DM, Fossella FV, Umsawasdi T, Murphy WK, Chasen MH, Walsh G, Kornaki R, McMurtrey MJ, Hong WK: Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable of metastatic malignant pleural mesothelioma. Cancer 76: 2230-2236, 1995
5. Von Hoff DD, Layard MW, Basa P, Davis HL Jr., Von Hoff AL, Rozencweig M, Muggia FM: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91: 710, 1979
6. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ, Liang LJ: Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitunior activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15: 987-993, 1997
7. Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, Libson E, Muggia FM, Gabizon A: Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 13: 1777-1785, 1995